88 related articles for article (PubMed ID: 8030108)
1. CD3 antigen modulation in T-lymphocytes during OKT3 treatment.
Magnussen K; Klug B; Møller B
Transplant Proc; 1994 Jun; 26(3):1731. PubMed ID: 8030108
[No Abstract] [Full Text] [Related]
2. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
3. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
4. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
5. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine E; Bellakoul R; Berthoux F
Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
[No Abstract] [Full Text] [Related]
6. Monitoring OKT3 treatment: pharmacodynamic and pharmacokinetic measures.
Henell KR; Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):83-5. PubMed ID: 8465435
[No Abstract] [Full Text] [Related]
7. Monoclonal antibodies in organ transplantation.
Valdés RH
Transplant Proc; 1996 Dec; 28(6):3293. PubMed ID: 8962277
[No Abstract] [Full Text] [Related]
8. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
9. Rationale for OKT3 monoclonal antibody treatment in transplant patients.
Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):1-3. PubMed ID: 8465414
[No Abstract] [Full Text] [Related]
10. Prolonged and repeated courses of OKT3 after liver transplantation.
Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
[No Abstract] [Full Text] [Related]
11. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
12. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
13. Inducible IL-2 on CD8 lymphocytes as a postoperative predictor of rejection in renal allograft recipients.
Langley J; Dickerman R; Vergne-Marini P; Williams J; Jensik S; Kenyon N; Anderson J
Transplant Proc; 1993 Feb; 25(1 Pt 2):939-43. PubMed ID: 8442275
[No Abstract] [Full Text] [Related]
14. Humoral immune response against OKT3.
Chatenoud L
Transplant Proc; 1993 Apr; 25(2 Suppl 1):68-73. PubMed ID: 8465430
[No Abstract] [Full Text] [Related]
15. Increased levels of sTNF receptors following OKT3 treatment.
Bemelman FJ; Jansen J; van der Poll T; Hack CE; van Deventer SJ; ten Berge RJ
Transplant Proc; 1994 Dec; 26(6):3094-5. PubMed ID: 7998082
[No Abstract] [Full Text] [Related]
16. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
17. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 antibodies.
Chatenoud L; Bach JF
Immunol Ser; 1993; 59():175-91. PubMed ID: 8461387
[No Abstract] [Full Text] [Related]
19. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
20. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
